NCT05683444View on ClinicalTrials.gov

Octreotide Improves Human Lymphatic Fluid Transport a Translational Trial

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

July 1, 2020

Primary Completion Date

March 26, 2021

Study Completion Date

March 26, 2021

Conditions
Lymphatic DiseasesChylothorax
Interventions
DRUG

Octreotide infusion

Octreotide infusion for 2,5 hours. 300 ng/kg/min bolus was given for the first 15 minutes and then a continuous infusion of 100 ng/kg/min for the remaining 135 minutes.

DRUG

Saline infusion

Saline Infusion

Trial Locations (1)

2100

Rigshospitalet, København Ø

All Listed Sponsors
collaborator

University of Aarhus

OTHER

collaborator

Bispebjerg Hospital

OTHER

lead

Rigshospitalet, Denmark

OTHER

NCT05683444 - Octreotide Improves Human Lymphatic Fluid Transport a Translational Trial | Biotech Hunter | Biotech Hunter